Circulating epithelial tumor cells as a prognostic tool for malignant melanoma

Melanoma Research
Katharina PachmannMartin Kaatz

Abstract

Although immune therapies with checkpoint inhibitors have gained increasing attention in advanced and metastatic melanoma, interferon-α remains a standard therapy for nonmetastatic malignant melanoma with risk factors. Interferons can successfully prevent relapse; however, the response rate is still not as high as would be desired. Prognostic tools to predict the response are required, which could lead to more individualized treatment regimens. In numerous studies over the past decade, circulating epithelial tumor cells (CETCs) have been shown to be a promising biomarker for estimating the risk of metastatic relapse, and we sought to determine whether they can also be used for this purpose in malignant melanoma. To establish a prognostic tool for patients with melanoma, we quantified CETCs over the course of interferon treatment in 49 patients. Patients were categorized into two groups according to the behavior of their circulating tumor cells during the interferon treatment: those with increasing and those with decreasing numbers of circulating tumor cells. Patients with increasing numbers of circulating tumor cells had a significantly higher risk of relapse. Kaplan-Meier survival analysis showed a significant difference betwe...Continue Reading

References

Aug 26, 1998·The American Journal of Surgical Pathology·K J BusamA A Jungbluth
Oct 8, 2003·The Oncologist·Michael S Sabel, Vernon K Sondak
Aug 20, 2004·The New England Journal of Medicine·Massimo CristofanilliDaniel F Hayes
Mar 8, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katharina PachmannKlaus Höffken
Mar 20, 2008·Advances in Experimental Medicine and Biology·Ulrike Leiter, Claus Garbe
Oct 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Johann S de BonoDerek Raghavan
Mar 14, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S J CohenN J Meropol
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles M BalchVernon K Sondak
Jun 11, 2010·The Journal of Investigative Dermatology·Vincenzo De GiorgiDaniela Massi
Sep 18, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Claus GarbeUNKNOWN European Organization of Research and Treatment of Cancer
Sep 26, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sojun HoshimotoDave S B Hoon
Sep 14, 2013·Science·Vicki PlaksZena Werb
Jun 8, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L KhojaA Fusi
Jul 28, 2016·Journal of Cancer Research and Therapeutics·Kaptan G LbenSevim Turanlı
Jan 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L KhojaA Fusi

❮ Previous
Next ❯

Citations

Aug 31, 2019·Expert Review of Molecular Diagnostics·Ernest Y Lee, Rajan P Kulkarni

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.